The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 67 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Bone Density Conservation Agents  [Clear All Filters]
2020
Makras, P., Babis G. C., Chronopoulos E., Karachalios T., Kazakos K., Paridis D., et al. (2020).  Experience gained from the implementation of the fracture liaison service in Greece.. Arch Osteoporos. 15(1), 12.
2019
Fontalis, A., Kenanidis E., Kotronias R. Angelos, Papachristou A., Anagnostis P., Potoupnis M., et al. (2019).  Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss.. Expert Opin Pharmacother. 20(9), 1123-1134.
Anagnostis, P., Gkekas N. K., Potoupnis M., Kenanidis E., Tsiridis E., & Goulis D. G. (2019).  New therapeutic targets for osteoporosis.. Maturitas. 120, 1-6.
2018
Anagnostis, P., Paschou S. A., Gkekas N. N., Artzouchaltzi A-M., Christou K., Stogiannou D., et al. (2018).  Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.. Endocrine. 60(3), 373-383.
Polyzos, S. A., & Terpos E. (2018).  Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis.. Endocrine. 62(2), 487-489.
Fontalis, A., Kenanidis E., Prousali E., Potoupnis M., & Tsiridis E. (2018).  Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis.. Expert Opin Drug Saf. 17(4), 413-428.
Anastasilakis, A. D., Polyzos S. A., & Makras P. (2018).  THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.. Eur J Endocrinol. 179(1), R31-R45.
2017
Kyrgidis, A., Yavropoulou M. P., Lagoudaki R., Andreadis C., Antoniades K., & Kouvelas D. (2017).  Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.. Osteoporos Int. 28(3), 991-999.
2016
Polyzos, S. A., & Terpos E. (2016).  Clinical vertebral fractures following denosumab discontinuation.. Endocrine. 54(1), 271-272.
Makras, P., Polyzos S. A., & Anastasilakis A. D. (2016).  Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.. J Clin Endocrinol Metab. 101(9), L89-90.
2015
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Anastasilakis, A. D., Polyzos S. A., Efstathiadou Z. A., Savvidis M., Sakellariou G. T., Papatheodorou A., et al. (2015).  Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.. Metabolism. 64(10), 1291-7.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Saridakis Z. G., Digkas D., Bisbinas I., et al. (2015).  Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.. Osteoporos Int. 26(10), 2521-7.
Dounousi, E., Leivaditis K., Eleftheriadis T., & Liakopoulos V. (2015).  Osteoporosis after renal transplantation.. Int Urol Nephrol. 47(3), 503-11.
2014
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Bisbinas I., Katsarou A., et al. (2014).  Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.. Osteoporos Int. 25(5), 1633-42.
Anastasilakis, A. D., Polyzos S. A., Makras P., Savvides M., Sakellariou G. T., Gkiomisi A., et al. (2014).  Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.. Horm Metab Res. 46(2), 145-9.
Polyzos, S. A., Singhellakis P. N., Naot D., Adamidou F., Malandrinou F. C., Anastasilakis A. D., et al. (2014).  Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene).. J Clin Endocrinol Metab. 99(3), 703-7.
Anagnostis, P., Karras S. N., & Goulis D. G. (2014).  Monitoring the efficacy of once-weekly teriparatide. Are bone turnover markers useful in predicting fracture risk?. Curr Med Res Opin. 30(6), 1177-8.
2013
Kyrkos, M. J., Papavasiliou K. A., Kenanidis E., Tsiridis E., Sayegh F. E., & Kapetanos G. A. (2013).  Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. In vivo, prospective study.. Osteoarthritis Cartilage. 21(7), 973-80.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Savvides M., Papatheodorou A., et al. (2013).  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.. Osteoporos Int. 24(7), 2127-32.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.
Glüer, C-C., Marin F., Ringe J. D., Hawkins F., Möricke R., Papaioannu N., et al. (2013).  Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.. J Bone Miner Res. 28(6), 1355-68.
Farahmand, P., Marín F., Hawkins F., Möricke R., Ringe J. D., Glüer C-C., et al. (2013).  Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.. Osteoporos Int. 24(12), 2971-81.
Anagnostis, P., Vyzantiadis T-A., Charizopoulou M., Adamidou F., Karras S., Goulis D. G., et al. (2013).  The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.. Thromb Haemost. 110(2), 257-63.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2013).  Serum sclerostin levels following treatment with parathyroid hormone.. J Endocrinol Invest. 36(4), 280.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.